A Swedish SME - with a novel and unique construct of a medical device to prevent artificial hip joint dislocation - offers a suitable party to buy the invention/medical device, including IPR-rights.

A Swedish SME – including an associated team member within Orthopaedics, a former professor of Orthopaedics at Karolinska Institute, Stockholm, and as well licensed physician/doctor - is offering a unique construct /medical device preventing artificial hip joint dislocation. During many years of work in orthopaedic operative units, the head of the SME has identified the problem in dislocating total hip prostheses (THP). He has gained insights into the causes of this issue and has developed a well-functioning invention to solve the problems for dislocating of THP. The problem of dislocating hip prostheses is well known in orthopaedics, primarily in patients after hip fracture but also, to a relatively lesser extend in patient operated for osteoarthritis (OA). In Sweden, about 18 000 hip fractures occur every year, of these about 50% hit the femoral neck proper and of these about 25% are treated with a THP. Due to age and poor muscular control these artificial hip joints are prone to dislocations. About the same number of THPs, 18 000, are performed due to OA. These also are at risk to dislocate but to a lesser extent. Due to the much larger total number of THPs for OA, these patients are perhaps more common at the emergency wards. The treatment is usually in-patient total anaesthesia and reposition of the hip. Less often a re-operation proper is necessary where one or both prosthetic components are replaced. Such reoperations are performed in 250-300 cases/years (Swedish Hip registry). The number of closed reposition under anaesthesia is ≈ 5-10 times larger. An advantage of the Innovation is that it can be inserted as a secondary procedure in cases with multiple dislocations. This constitutes an open, invasive procedure but is much smaller than revision of the entire prosthetic construct. In total, in Sweden, the number of THP for hip fractures + multiple dislocations (fracture and OA) can be coarsely assessed to be 2500-3500. The volume of possible preventive use of this invention in THP for OA is in this stage of development harder to estimate. To give a rough calculation of the total international market it´s worth having in mind that Sweden's population is 10 million people. Like many other countries, Sweden's population is getting older. By the year 2070, the proportion of older people is expected to have increased sharply, while the proportion of people of working age will decrease. I.e., the numbers above should at least be multiplied with the numbers in relation to the existing population in Sweden, on the most valuable markets. That is to say - the market opportunity is growing for this medical device. The innovation allows some motion between the acetabular cup and the femoral head. The dislocating forces can be enormous and risk breaking any constraint. Therefore, the motions allowed be a safe-guard and precautionary measure. From a manufacturing perspective, the device is rather simple and production costs should be low. The Swedish company is now offering the invention on the market, with the intention to find a purchaser of the applied patents. The intended buying partner should preferably have a history of working within the field of orthopaedic implants with development from prototype to final market including among others final engineering design, adaption to production, production, regulatory, clinical studies, market activities and selling via B2B on the worldwide market.